Skip to main content
SpringerLink
Log in
Book cover

Thyroid Cancer pp 289–292Cite as

Follow-Up Strategy in Papillary Thyroid Cancer

  • Chapter

Abstract

Effective surveillance for recurrent papillary thyroid cancer begins with an assessment of the risk of recurrence or death from disease, depending on individual characteristics of patients and their tumor. This information is used to determine an appropriate level of follow-up, which may vary from as little as an annual neck examination on replacement thyroid hormone therapy for occult lesions, to annual or semiannual thyrotropin (TSH) stimulated whole-body scan (WBS) and thyroglobulin (Tg) measurement for high-risk patients. Effective follow-up is also contingent upon a current understanding of the strengths and limitations of the tools available for thyroid cancer surveillance. This chapter focuses on the rationale used to determine the method and frequency of follow-up for patients with papillary thyroid cancer and reviews current guidelines regarding surveillance for persistent or recurrent disease.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   269.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   339.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Mazzaferri EL, Kloos RT. Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001; 86:1447–1463.

    Article  PubMed  CAS  Google Scholar 

  2. Solomon BL, Wartofsky L, Burman KD. Current trends in the management of well differentiated papillary thyroid carcinoma. J Clin Endocrinol Metab 1996; 81:333–339.

    Article  PubMed  CAS  Google Scholar 

  3. Cailleux AF, Baudin E, Travagli JP, et al. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? J Clin Endocrinol Metab 2000; 85:175–178.

    Article  PubMed  CAS  Google Scholar 

  4. Mazzaferri EL, Kloos RT. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation? J Clin Endocrinol Metab 2002; 87:1490–1498.

    Article  PubMed  CAS  Google Scholar 

  5. Robbins RJ, Chon JT, Fleisher M, et al. Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma? J Clin Endocrinol Metab 2002; 87:3242–3247.

    Article  PubMed  CAS  Google Scholar 

  6. Bajen MT, Mane S, Munoz A, Garcia JR. Effect of a diagnostic dose of 185 MBq 131I on postsurgical thyroid remnants. J Nucl Med 2000; 41:2038–2042.

    PubMed  CAS  Google Scholar 

  7. Kao CH, Yen TC. Stunning effects after a diagnostic dose of iodine-131. Nuklearmedizin. 1998; 37:30–32.

    PubMed  CAS  Google Scholar 

  8. Lees W, Mansberg R, Roberts J, et al. The clinical effects of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I. Eur J Nucl Med Mol Imaging 2002; 29:1421–1427.

    Article  PubMed  CAS  Google Scholar 

  9. Leger FA, Izembart M, Dagousset F, et al. Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma. Eur J Nucl Med 1998; 25:242–246.

    Article  PubMed  CAS  Google Scholar 

  10. Park HM, Park YH, Zhou XH. Detection of thyroid remnant/metastasis without stunning: an ongoing dilemma. Thyroid 1997; 7:277–280.

    Article  PubMed  CAS  Google Scholar 

  11. Mandel SJ, Shankar LK, Benard F, et al. Superiority of iodine-123 compared with iodine-131 scanning for thyroid remnants in patients with differentiated thyroid cancer. Clin Nucl Med 2001; 26:6–9.

    Article  PubMed  CAS  Google Scholar 

  12. Ladenson PW, Braverman LE, Mazzaferri EL, et al. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med 1997; 337:888–896.

    Article  PubMed  CAS  Google Scholar 

  13. Haugen BR, Pacini F, Reiners C, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 1999; 84:3877–3885.

    Article  PubMed  CAS  Google Scholar 

  14. Wartofsky L. Management of low-risk well-differentiated thyroid cancer based only on thyroglobulin measurement after recombinant human thyrotropin. Thyroid. 2002; 12:583–590.

    Article  PubMed  CAS  Google Scholar 

  15. Torrens JI, Burch HB. Serum thyroglobulin measurement. Utility in clinical practice. Endocrinol Metab Clin North Am 2001; 30:429–467.

    Article  PubMed  CAS  Google Scholar 

  16. Mazzaferri EL, Robbins RJ, Spencer CA, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2003; 88:1433–1441.

    Article  PubMed  CAS  Google Scholar 

  17. National Comprehensive Cancer Network (NCCN) Thyroid Carcinoma: Clinical Practice Guidelines 2005, J Natl Comprehensive Cancer Network 2005; 3:404–457.

    Google Scholar 

  18. AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. American Association of Clinical Endocrinologists. American College of Endocrinology. Endocr Pract 2001; 7:202–220.

    Google Scholar 

  19. Kendall-Taylor P. Guidelines for the management of thyroid cancer. Clin Endocrinol 2003; 58:400–402.

    Article  Google Scholar 

  20. David A, Blotta A, Rossi R, et al. Clinical value of different responses of serum thyroglobulin to recombinant human thyrotropin in the follow-up of patients with differentiated thyroid carcinoma. Thyroid 2005; 15:267–273.

    Article  PubMed  CAS  Google Scholar 

  21. Ain KB. Papillary thyroid carcinoma. Etiology, assessment, and therapy. Endocrinol Metab Clin North Am 1995; 24:711–760.

    PubMed  CAS  Google Scholar 

  22. Mazzaferri EL. Long-term outcome of patients with differentiated thyroid carcinoma: effect of therapy. Endocr Pract 2000; 6:469–476.

    PubMed  CAS  Google Scholar 

  23. Hay ID. Papillary thyroid carcinoma. Endocrinol Metab Clin North Am. 1990; 19:545–576.

    PubMed  CAS  Google Scholar 

  24. Grunwald F, Schomburg A, Bender H, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 1996; 23:312–319.

    Article  PubMed  CAS  Google Scholar 

  25. Sisson JC, Ackermann RJ, Meyer MA, Wahl RL. Uptake of 18-fluoro-2-deoxy-D-glucose by thyroid cancer: implications for diagnosis and therapy. J Clin Endocrinol Metab 1993; 77:1090–1094.

    Article  PubMed  CAS  Google Scholar 

  26. Chung JK, So Y, Lee JS, et al. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan. J Nucl Med 1999; 40:986–992.

    PubMed  CAS  Google Scholar 

  27. Chin BB, Patel P, Cohade C, et al. Recombinant human thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in well-differentiated thyroid carcinoma. J Clin Endocrinol Metab 2004; 89:91–95.

    Article  PubMed  CAS  Google Scholar 

  28. Yeo JS, Chung JK, So Y, et al. F-18-fluorodeoxyglucose positron emission tomography as a presurgical evaluation modality for I-131 scan-negative thyroid carcinoma patients with local recurrence in cervical lymph nodes. Head Neck 2001; 23:94–103.

    Article  PubMed  CAS  Google Scholar 

  29. Wang W, Larson SM, Fazzari M, et al. Prognostic value of [18F] fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab 2000; 85:1107–1113.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Endocrinology Division, Department of Medicine, Walter Reed Army Medical Center, USA

    Henry B. Burch MD (Chief, Associate Professor of Medicine)

  2. Uniformed Services University of the Health Sciences, Bethesda, MD

    Henry B. Burch MD (Chief, Associate Professor of Medicine)

Authors
  1. Henry B. Burch MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Washington Hospital Center, Washington, DC

    Leonard Wartofsky MD, MPH, MACP  & Douglas Van Nostrand MD, FACP, FACNP  & 

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Burch, H.B. (2006). Follow-Up Strategy in Papillary Thyroid Cancer. In: Wartofsky, L., Van Nostrand, D. (eds) Thyroid Cancer. Humana Press. https://doi.org/10.1007/978-1-59259-995-0_28

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-995-0_28

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-462-3

  • Online ISBN: 978-1-59259-995-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation